Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.

Abstract

Despite attaining LDL-cholesterol targets, many patients with diabetes remain at risk of developing cardiovascular events. In addition, treatment with statins has been associated with a slight but significant increased risk of development of diabetes, particularly with high-intensity statins. Pitavastatin is a moderate- to high-intensity statin that effectively reduces LDL-cholesterol levels. Pitavastatin provides a sustained increase of HDL-cholesterol levels that may exhibit a neutral or positive effect on glucose metabolism, may not increase the risk of new-onset diabetes, may exhibit positive effects on renal function and urinary albumin excretion and the risk of drug-drug interactions is low. Therefore, it seems that pitavastatin should preferentially be considered in the treatment of dyslipidemia in diabetic patients or at risk of developing diabetes.

• Authors: Vivencio Barrios, Carlos Escobar
• Journal: Future cardiology (Future Cardiol) Vol. 12 Issue 4 Pg. 449-66 (07 2016) ISSN: 1744-8298 [Electronic] England
• PMID: 27076402 (Publication Type: Journal Article, Review)

Chemical References

• Cholesterol, HDL
• Cholesterol, LDL
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Quinolines
• pitavastatin

Topics

• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Diabetes Mellitus (blood)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Hypercholesterolemia (blood, drug therapy)
• Quinolines (therapeutic use)